Operating in a high-entry-barrier, oligopolistic market, Truenat was the result of 13 years of rigorous research and development, culminating in certification and validation for TB testing by the Indian Council of Medical Research (ICMR).
Today, we are one of only two rapid molecular diagnostic platforms globally endorsed by the World Health Organization (WHO) for the initial detection of tuberculosis and rifampicin resistance.
Protected by patents in over 100 countries, Truenat enables diagnosis of a wide range of infectious and non-communicable diseases such as tuberculosis, COVID, Hepatitis B and C, Human immunodeficiency virus, Human Papillomavirus, etc.
At Molbio, we’re redefining the way delivery of healthcare addresses real-world challenges, creating a legacy of innovation that spans across generations.
Innovating in over 55 countries, bridging gaps, and connecting communities with transformative solutions.
Over 40 million individuals empowered with real-time, actionable diagnostics that make every moment count.
Bringing advanced technology to the most remote corners, ensuring healthcare is within reach for all.
Diagnostics that break free from the constraints of traditional lab infrastructure.
Empowering diagnosis and treatment in a single visit, with tools to track progress effectively.
Delivering gold-standard testing that’s accessible to all.
Mapping disease hotspots, uncovering emerging needs, and delivering innovative solutions.
Connect with us
Molbio Diagnostics Limited
(Formerly Molbio Diagnostics Private Limited)
© All Rights Reserved
ShanMukha has emerged as a crucial partner in advancing diagnostic technology innovation. The organization specializes in developing cutting-edge medical devices and diagnostic solutions, bringing expertise in precision engineering and product development. ShanMukha’s technical prowess, combined with Molbio’s vision for democratizing diagnostics, has resulted in a robust and user-friendly diagnostic solutions for healthcare providers worldwide, enhancing the accessibility and efficiency of molecular diagnostic platforms.
CrisprBits is one of the first Indian companies to use CRISPR, a groundbreaking gene-editing technology, to create high-quality solutions in life sciences. Specialised in developing CRISPR-based diagnostic tools, and this partnership is another step toward Molbio’s commitment to providing accurate medicine through advanced technology.
The United States Agency for International Development (USAID) is a leading funder of global efforts to combat tuberculosis (TB), HIV, and malaria. Since 2023, USAID has been a strategic partner of Molbio in expanding its global footprint and improving access to quality diagnostics in developing regions. Through the Introducing New Tools Project (iNTP), a collaboration with the Stop TB Partnership, Molbio’s Truenat was introduced as part of the latest innovations and rolled out across 11 high burden TB countries, strengthening countries’ capacity to respond to one of the leading causes of infectious disease mortality globally.
As a global organization dedicated to eliminating tuberculosis, the Stop TB Partnership has been a close ally of Molbio in its mission to democratize gold-standard molecular diagnostics for TB and expand access worldwide. Stop TB, along with USAID, has been instrumental in strengthening the TB diagnostics network in the most affected communities.
TESTi Technologies is a Finnish innovation company, known for its flagship product PROMILLESS – a saliva-based diagnostics test to measure body alcohol content. Molbio with this strategic partnership, aims to bring this Finnish technology to the masses in the country by manufacturing and commercializing PROMILLESS.
The Global Fund is a multilateral funding agency for global health that pools the world’s resources to invest strategically in programs to fight major killers in low—and middle-income countries: HIV, tuberculosis (TB), and malaria. Since 2002, the Global Fund has disbursed more than US$65 billion to governments to respond to public health crises, strengthen health infrastructure, and ensure a healthier, safer, more equitable future for all.
The collaboration with the Global Fund has significantly expanded the reach of Molbio’s flagship multi-disease molecular diagnostic solution in high-disease-burden countries, enabling it to bridge critical diagnostic gaps of resource-limited settings and improve timely detection and treatment strategies.
